The U.S. Food and Drug Administration (FDA) is warning consumers not to purchase or use Skin-Cap aerosol spray products, sold by Chemigroup France (formerly Cheminova Laboratories), after testing revealed the presence of an undisclosed high-potency steroid. The product, marketed for skin conditions such as psoriasis, eczema, and dermatitis, was found on websites including skincap.com, Amazon, and Walmart.
FDA testing discovered that the spray contains glucocorticosteroids, a class of drugs with immunosuppressive and anti-inflammatory properties, which are not listed on the product’s label. Prolonged or improper use of topical steroids can lead to serious health issues, including skin thinning, increased blood sugar, blood pressure changes, bone damage, and psychiatric effects.
While no adverse events have been reported, the FDA urges users to consult their healthcare providers for guidance and to report any side effects to the FDA’s MedWatch program.
